BARCLAYS PLC - TCR2 THERAPEUTICS INC ownership

TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 58 filers reported holding TCR2 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of TCR2 THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$50
+51.5%
33,1160.0%0.00%
Q4 2022$33
-99.9%
33,116
-1.3%
0.00%
Q3 2022$60,000
-41.7%
33,561
-5.5%
0.00%
Q2 2022$103,000
-7.2%
35,525
-12.2%
0.00%
Q1 2022$111,000
-75.8%
40,477
-58.8%
0.00%
Q4 2021$458,000
+63.0%
98,142
+197.1%
0.00%
Q3 2021$281,000
-59.5%
33,032
-21.8%
0.00%
Q2 2021$694,000
-35.6%
42,235
-13.4%
0.00%
-100.0%
Q1 2021$1,077,000
+205.1%
48,779
+326.6%
0.00%
Q4 2020$353,000
+16.1%
11,435
-23.7%
0.00%
Q3 2020$304,000
+120.3%
14,996
+67.2%
0.00%
Q2 2020$138,000
+360.0%
8,969
+130.4%
0.00%
Q1 2020$30,000
-82.2%
3,893
-67.2%
0.00%
Q4 2019$169,000
+89.9%
11,885
+102.0%
0.00%
Q3 2019$89,000
+456.2%
5,885
+402.1%
0.00%
Q2 2019$16,000
-60.0%
1,172
-49.4%
0.00%
Q1 2019$40,0002,3180.00%
Other shareholders
TCR2 THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
MPM BioImpact LLC 6,741,964$208,528,00018.01%
MPM ASSET MANAGEMENT LLC 4,050,865$125,293,00017.73%
Consonance Capital Management LP 584,885$71,268,0006.66%
SILVERARC CAPITAL MANAGEMENT, LLC 136,000$4,206,0002.44%
Redmile Group, LLC 2,832,888$87,621,0001.06%
Altium Capital Management LP 73,991$2,289,0000.86%
PFM Health Sciences, LP 775,794$23,995,0000.84%
Soleus Capital Management, L.P. 199,867$6,182,0000.82%
MOODY ALDRICH PARTNERS LLC 123,639$3,824,0000.62%
Sofinnova Investments, Inc. 333,707$10,322,0000.61%
View complete list of TCR2 THERAPEUTICS INC shareholders